SCHEMBL1391233

SCHEMBL1391233

CCOc1nc(NCc2ccco2)nc(Nc2ccccc2-c2cccnc2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ MAPT P10636 7/20 0.58
▸ MAPK1 P28482 6/20 0.58
▸ ALDH1A1 P00352 4/20 0.58
▸ NPSR1 Q6W5P4 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ HTT P42858 1/20 0.53
▸ KCNH3 Q9ULD8 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.45
▸ GAA P10253 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ CLK1 P49759 1/20 0.45
▸ HBB P68871 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ PDE5A O76074 1/20 0.44
▸ FYN P06241 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1390817 0.85 MAPT (0.70) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1391547 0.81 MAPK1 (0.64) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1391154 0.80 SMN1; SMN2 (0.77) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL10243636 0.79 MAPT (0.79) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1391275 0.78 MAPT (0.74) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1390906 0.78 MAPT (0.57) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1391281 0.77 ALDH1A1 (0.56) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1391323 0.77 SMN1; SMN2 (0.76) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1390720 0.77 MAPT (0.78) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1
SCHEMBL1391101 0.74 MAPT (0.78) SMN1; SMN2MAPTMAPK1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
EP-2231624-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF Progenics Pharmaceuticals, Inc. (US) 2010-09-29 — — EP disclosed
WO-2009091388-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF PROGENICS PHARMACEUTICALS, INC. (US) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS SMN1; SMN2 4526/4885MAPT 3654/4885MAPK1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback